XML 83 R69.htm IDEA: XBRL DOCUMENT v3.19.1
Lines of Credit and Long-Term Debt - Long-Term Debt - Additional Information (Details)
1 Months Ended 3 Months Ended
Dec. 31, 2018
USD ($)
Sep. 30, 2018
USD ($)
Jul. 31, 2018
USD ($)
day
$ / shares
Mar. 31, 2019
USD ($)
Mar. 31, 2018
USD ($)
Debt Instrument [Line Items]          
Proceeds from long-term debt, net of issuance costs       $ 376,000 $ 0
Deferred income taxes       508,000 4,074,000
Interest expense       4,311,000 $ 99,000
Long-term debt $ 211,794,000     214,574,000  
Convertible debt          
Debt Instrument [Line Items]          
Long-term debt 203,391,000     205,829,000  
Royalty-based financing          
Debt Instrument [Line Items]          
Long-term debt 2,085,000     2,151,000  
ActoBio Therapeutics Inc. | Convertible debt | Harvest Intrexon Enterprise Fund I, LP          
Debt Instrument [Line Items]          
Debt instrument, interest rate, stated percentage   3.00%      
Interest expense       225,000  
Long-term debt       $ 30,515,000  
Trans Ova Genetics, LC | Notes payable to banks | American State Bank          
Debt Instrument [Line Items]          
Debt instrument, interest rate, stated percentage       3.95%  
Long-term debt       $ 4,382,000  
Debt instrument, periodic payment       39,000  
AquaBounty Technologies, Inc. | Royalty-based financing | Atlantic Canada Opportunities Agency          
Debt Instrument [Line Items]          
Long-term debt       $ 2,151,000  
Royalty on products, percentage       10.00%  
Harvest Intrexon Enterprise Fund I, LP | ActoBio Therapeutics Inc.          
Debt Instrument [Line Items]          
Long-term debt issued to a related party in an asset acquisition   $ 30,000,000      
3.5% Convertible Notes Due 2023          
Debt Instrument [Line Items]          
Aggregate principal amount     $ 200,000,000 $ 200,000,000  
Debt instrument, interest rate, stated percentage     3.50% 3.50%  
Proceeds from long-term debt, net of issuance costs     $ 193,958,000    
Debt issuance costs     $ 6,042,000    
Conversion rate     58.6622    
Principal amount used in conversion     $ 1,000    
Conversion price (in usd per share) | $ / shares     $ 17.05    
Debt instrument redemption price, percentage     100.00%    
Carrying value of convertible debt 148,101,000   $ 143,723,000 $ 150,314,000  
Equity component of convertible debt, net of issuance costs and deferred taxes     50,235,000    
Deferred income taxes     $ 13,367,000    
Effective interest rate on convertible notes       11.02%  
Convertible notes, unamortized discount and issuance costs       $ 49,686,000  
Total interest expense       3,963,000  
Interest expense payable in cash       1,750,000  
Noncash interest expense       2,213,000  
3.5% Convertible Notes Due 2023 | Other Accrued Liabilities          
Debt Instrument [Line Items]          
Accrued interest payable in cash       $ 1,750,000  
3.5% Convertible Notes Due 2023 | Minimum          
Debt Instrument [Line Items]          
Common stock price trading days | day     20    
Common stock price consecutive trading days | day     30    
Percentage of common share price over conversion price for conversion     130.00%    
3.5% Convertible Notes Due 2023 | Maximum          
Debt Instrument [Line Items]          
Common stock price trading days | day     5    
Common stock price consecutive trading days | day     5    
Debt instrument redemption price, percentage     98.00%    
Merck Convertible Note          
Debt Instrument [Line Items]          
Aggregate principal amount $ 25,000,000        
Conversion rate upon IPO 0.90        
Interest rate applicable to IPO conversion event 0.05